Cargando…
Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders
In recent years, the exploration of regulatory T cell (Treg)-based cellular therapy has become an attractive strategy to ameliorate inflammation and autoimmunity in various clinical settings. The main obstacle to the clinical application of Treg in human is their low number circulating in peripheral...
Autores principales: | Wiesinger, Manuel, Stoica, Diane, Roessner, Susanne, Lorenz, Carmen, Fischer, Anika, Atreya, Raja, Neufert, Clemens F., Atreya, Imke, Scheffold, Alexander, Schuler-Thurner, Beatrice, Neurath, Markus F., Schuler, Gerold, Voskens, Caroline J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662555/ https://www.ncbi.nlm.nih.gov/pubmed/29123521 http://dx.doi.org/10.3389/fimmu.2017.01371 |
Ejemplares similares
-
Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial
por: Voskens, Caroline J, et al.
Publicado: (2021) -
Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo
por: Fischer, Anika, et al.
Publicado: (2016) -
Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis
por: Voskens, Caroline, et al.
Publicado: (2023) -
Increased Motility and Suppression of Ex Vivo–Expanded Regulatory T Cells Designed for Adoptive Transfer Therapy in Ulcerative Colitis
por: Müller, Tanja M., et al.
Publicado: (2023) -
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
por: Fuchs, Friederike, et al.
Publicado: (2017)